| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/07/2022 | 7.59% | Cantor Fitzgerald | $2.5 → $0.17 | Downgrades | Overweight → Neutral |
| 11/29/2021 | 849.37% | JMP Securities | → $1.5 | Initiates Coverage On | → Outperform |
| 01/22/2021 | 1798.73% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 01/21/2021 | 1798.73% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 06/26/2020 | 1640.51% | Alliance Global Partners | → $2.75 | Initiates Coverage On | → Buy |
iBio Questions & Answers
The latest price target for iBio (AMEX: IBIO) was reported by Cantor Fitzgerald on October 7, 2022. The analyst firm set a price target for $0.17 expecting IBIO to rise to within 12 months (a possible 7.59% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for iBio (AMEX: IBIO) was provided by Cantor Fitzgerald, and iBio downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iBio was filed on October 7, 2022 so you should expect the next rating to be made available sometime around October 7, 2023.
While ratings are subjective and will change, the latest iBio (IBIO) rating was a downgraded with a price target of $2.50 to $0.17. The current price iBio (IBIO) is trading at is $0.16, which is out of the analyst's predicted range.